Invest in Neurocarrus

New first-in-class sensory neuron specific pain drug treats pain without risk of addiction

$32,650

reserved of a $55,000 goal
INVESTMENT TERMS
Future Equity
$11.25M valuation cap

Highlights

1
Drug candidate N-001 provides relief from severe pain in animals caused by inflammation or surgery.
2
N-001 cannot enter the brain and therefore cannot cause addiction.
3
N-001 provides pain relief equal to prescription drugs without side effects on muscles or balance.
4
N-001 is a targeted drug with a unique manufacturing process to discourage competitors.

Our Team


Publications:

Animal efficacy and safety studies

Targeting, mechanism, and efficacy studies

Drug design and engineering studies

















Downloads

Overview